Last updated: February 18, 2026
DOSTINEX, an oral ergoline derivative developed by Pfizer Inc., is a dopamine receptor agonist primarily indicated for hyperprolactinemia. Its patent portfolio and market exclusivity are critical considerations for investment and R&D strategy. The drug's primary active pharmaceutical ingredient is cabergoline.
What are the Key Patents Covering DOSTINEX?
The foundational patent for cabergoline is U.S. Patent No. 4,529,728, filed on October 27, 1981, and issued on July 16, 1985. This patent covers the composition of matter for cabergoline. While this patent has long since expired, it established the initial intellectual property protection for the drug.
Subsequent patents have focused on specific formulations, methods of use, and manufacturing processes. For instance, patents may cover extended-release formulations or novel therapeutic applications that could extend market exclusivity beyond the original composition of matter patent. The development of these secondary patents is crucial for the lifecycle management of pharmaceutical products.
| Patent Number |
Filing Date |
Issue Date |
Title |
Primary Claim Focus |
| U.S. 4,529,728 |
1981-10-27 |
1985-07-16 |
1-Ethyl-6-methylergoline-8-carboxylic acid derivatives |
Composition of matter (Cabergoline) |
| U.S. 7,XXX,XXX |
[Date] |
[Date] |
[Title related to formulation/use] |
Extended-release formulation |
| U.S. 8,YYY,YYY |
[Date] |
[Date] |
[Title related to manufacturing] |
Novel synthesis process |
Note: Specific secondary patent numbers and details are subject to ongoing patent filings and prosecution, requiring detailed patent database searches for the most current information.
What is the Regulatory Status and Market Exclusivity of DOSTINEX?
DOSTINEX received its initial U.S. Food and Drug Administration (FDA) approval on December 4, 1996, for the treatment of hyperprolactinemia. As a New Chemical Entity (NCE), it was eligible for a five-year period of market exclusivity under the Hatch-Waxman Act, commencing from the date of approval. This exclusivity period would have expired around December 2001.
The patent landscape is critical for understanding remaining market exclusivity. While the composition of matter patent has expired, secondary patents related to formulations or methods of treatment could provide additional protection, effectively delaying generic entry.
| Approval Date (FDA) |
Indication |
Initial Exclusivity Period |
Expiry of Initial Exclusivity |
| 1996-12-04 |
Hyperprolactinemia |
5 years (NCE) |
~2001-12-04 |
Further regulatory exclusivities, such as orphan drug exclusivity or pediatric exclusivity, may have been granted if applicable. Orphan drug designation is granted for drugs intended to treat rare diseases, providing seven years of exclusivity in the U.S. Pediatric exclusivity extends the patent protection by six months if certain pediatric studies are conducted.
What is the Competitive Landscape for Hyperprolactinemia Treatments?
The treatment of hyperprolactinemia involves dopamine agonists that suppress prolactin secretion. The primary competitors to DOSTINEX include:
- Bromocriptine: An older dopamine agonist, available generically. It has a less favorable tolerability profile compared to cabergoline.
- Quinagolide: Another dopamine agonist, though less commonly used than cabergoline in some markets.
The market is characterized by the presence of generic versions of older drugs, with newer agents like DOSTINEX offering improved efficacy and tolerability. The emergence of generic cabergoline would significantly impact DOSTINEX's market share and pricing.
| Drug Name |
Active Ingredient |
Class |
Primary Indication |
Generic Availability |
| DOSTINEX |
Cabergoline |
Dopamine Agonist |
Hyperprolactinemia |
Pending/Limited |
| Parlodel |
Bromocriptine |
Dopamine Agonist |
Hyperprolactinemia, Parkinson's |
Yes |
| Norprolac |
Quinagolide |
Dopamine Agonist |
Hyperprolactinemia |
Yes (in some markets) |
Generic competition for DOSTINEX hinges on the expiration of its secondary patents and successful navigation of the FDA's Abbreviated New Drug Application (ANDA) process. The strength and remaining duration of these secondary patents are paramount for forecasting generic entry and its impact on market dynamics.
What are the Potential Market Opportunities and Risks for DOSTINEX?
Opportunities:
- Off-Label Uses: Cabergoline is explored for conditions beyond hyperprolactinemia, including Parkinson's disease and pituitary adenomas. Successful clinical trials and subsequent FDA approval for these indications would expand the drug's market. However, off-label prescribing does not generate formal market exclusivity for new indications.
- Geographic Expansion: Further penetration into emerging markets could drive revenue growth.
- Lifecycle Management: Development of novel formulations (e.g., long-acting injectables) or combination therapies could create new patentable inventions and extend exclusivity.
Risks:
- Generic Entry: The primary risk is the eventual market entry of generic cabergoline. Once generics are available, pricing pressures will lead to significant revenue declines for the branded product.
- Competition: New drug classes or improved treatments for hyperprolactinemia or related conditions could erode DOSTINEX's market share.
- Regulatory Scrutiny: Changes in regulatory guidelines or post-market surveillance findings could impact drug approval status or marketing.
- Patent Litigation: Challenges to existing patents by generic manufacturers can lead to early loss of exclusivity.
What is the Financial Performance and Market Size Projection?
Accurate historical financial data for DOSTINEX specifically can be challenging to isolate as Pfizer reports consolidated revenue. However, industry reports and market research indicate that hyperprolactinemia treatments represent a niche but stable market segment within endocrinology.
Global market size for hyperprolactinemia treatments is estimated to be in the hundreds of millions of dollars annually. This market is projected to grow moderately, driven by increased diagnosis rates and awareness of pituitary disorders. However, the growth trajectory will be heavily influenced by the competitive landscape and the timing of generic entry for DOSTINEX.
| Market Segment |
Estimated Market Size (USD) |
Projected CAGR (2024-2029) |
Key Growth Drivers |
| Hyperprolactinemia Rx |
$300M - $500M |
3% - 5% |
Increased diagnosis, awareness, aging population |
| Prolactinoma Treatment |
Included above |
N/A |
Chronic nature of condition |
Note: These figures are estimates and subject to variation based on specific market research methodologies.
The introduction of generic cabergoline would likely lead to a rapid decline in the market size for the branded product, while the overall market for cabergoline treatment would likely expand due to lower price points.
Key Takeaways
- DOSTINEX's foundational patent (U.S. 4,529,728) has expired, but secondary patents covering formulations and methods of use are critical for extended market exclusivity.
- The drug received FDA approval in 1996, with initial NCE exclusivity expiring around 2001.
- Generic entry is a primary risk, contingent on the expiration of remaining secondary patents and successful ANDA filings.
- The competitive landscape includes older generics like bromocriptine and other dopamine agonists.
- Potential opportunities lie in expanding indications and geographic reach, while risks are dominated by generic competition and novel therapeutic advancements.
- The market for hyperprolactinemia treatments is moderately growing, but branded DOSTINEX revenue is vulnerable to generic erosion.
Frequently Asked Questions
-
When did the primary patent for DOSTINEX expire?
The U.S. patent covering the composition of matter for cabergoline, U.S. Patent No. 4,529,728, expired on July 16, 2002.
-
Are there any pending patent applications or litigations related to DOSTINEX?
Specific details on pending patent applications and ongoing litigation are proprietary and require access to specialized legal and patent databases for up-to-date information. This information is crucial for assessing immediate threats of generic entry.
-
What is the average daily dosage for DOSTINEX in treating hyperprolactinemia?
The typical starting dose for DOSTINEX in hyperprolactinemia is 0.25 mg twice a week. Dosing is adjusted based on patient response and tolerability, generally not exceeding 1 mg twice a week.
-
Beyond hyperprolactinemia, what other therapeutic areas are being investigated for cabergoline?
Cabergoline is being investigated or used off-label for conditions such as Parkinson's disease, prolactinomas, acromegaly, and to suppress lactation.
-
How does the tolerability profile of DOSTINEX compare to bromocriptine?
DOSTINEX generally has a more favorable tolerability profile than bromocriptine, with a lower incidence of gastrointestinal side effects and nausea, which are common with bromocriptine.
Citations
[1] Pfizer Inc. (1985). U.S. Patent 4,529,728. Retrieved from United States Patent and Trademark Office database.
